Peking University Researchers Unveil cf-EpiTracing Platform Detecting Complex Diseases From Single Blood Drop

Peking University's cf-EpiTracing platform uses a single drop of blood to identify tissue-specific disease signals, reaching 97% accuracy in cancer trials.

By: AXL Media

Published: Mar 17, 2026, 4:28 AM EDT

Source: Information for this report was sourced from Peking University

A Microscopic Breakthrough in Non-Invasive Diagnostic Precision

The landscape of liquid biopsies has shifted significantly following the introduction of cf-EpiTracing, a platform engineered to extract vast diagnostic data from a single drop of human blood. Developed by a collaborative team at Peking University led by Professor He Aibin and Professor Jing Hongmei, the technology addresses a long-standing limitation in blood testing by successfully pinpointing the exact biological source of disease signals. According to the research published in Nature, this capability allows clinicians to observe cellular distress with unprecedented clarity using as little as 50 microliters of plasma, effectively bridging the gap between simple detection and detailed tissue mapping.

The Evolution of Cell-Free Chromatin Analysis

Traditional liquid biopsies often struggle to provide a comprehensive narrative of a patient's internal health, frequently failing to identify which specific organs or tissues are driving a pathological process. The cf-EpiTracing system overcomes this hurdle by capturing intricate epigenetic fingerprints within cell-free chromatin, providing a more nuanced view than standard DNA sequencing. By analyzing these molecular markers, the researchers have created a method that does more than just flag the presence of a condition, it traces the signal back to its origin. This level of detail is essential for differentiating between similar disease states that require vastly different therapeutic interventions.

High Stakes Accuracy in Colorectal Cancer Screening

The practical application of this multi-omic approach has already yielded striking results in the realm of oncology, particularly regarding early detection of colorectal malignancies. By integrating multimodal epigenomic features with advanced machine learning algorithms, the platform achieved an accuracy rate of 97.6 percent during its initial training phase. Even when tested against independent validation groups, the system maintained a robust 92.2 percent success rate. This consistency suggests that the technology is not merely a laboratory curiosity but a viable candidate for large-scale clinical screening where early intervention is the primary factor in patient survival.